Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto Fronza

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
The Journal of Biological Chemistry|June 4, 2002
Influences of base excision repair defects on the lethality and mutagenicity induced by Me-lex, a sequence-selective N3-adenine methylating agentPaola Monti, Paola Campomenosi, Yari Ciribilli, et al.
Frontiers in Oncology|November 16, 2020
Heterogeneity of <i>TP53</i> Mutations and P53 Protein Residual Function in Cancer: Does It Matter?Paola Monti, Paola Menichini, Andrea Speciale, et al.
Scientific Reports|September 15, 2018
Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulationBarbara Marengo, Paola Monti, Mariangela Miele, et al.
Human Mutation|March 7, 2013
EEC- and ADULT-associated TP63 mutations exhibit functional heterogeneity toward P63 responsive sequencesPaola Monti, Debora Russo, Renata Bocciardi, et al.
Cells|January 12, 2021
Antitumor Effects of PRIMA-1 and PRIMA-1<sup>Met</sup> (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Paola Menichini, Paola Monti, Andrea Speciale, et al.
Nucleic Acids Research|July 30, 2013
Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence codeYari Ciribilli, Paola Monti, Alessandra Bisio, et al.
Journal of Personalized Medicine|February 10, 2021
Potential Role of miRNAs in the Acquisition of Chemoresistance in NeuroblastomaBarbara Marengo, Alessandra Pulliero, Maria Valeria Corrias, et al.
Frontiers in Immunology|September 8, 2023
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancersChiara M Biatta, Michele Paudice, Marco Greppi, et al.
European Journal of Haematology|March 4, 2021
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocolFortunato Morabito, Giovanni Tripepi, Ernesto Vigna, et al.
Non-Coding RNA|March 19, 2020
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical OutcomeDomenica Ronchetti, Vanessa Favasuli, Paola Monti, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
The Journal of Biological Chemistry|June 4, 2002
Influences of base excision repair defects on the lethality and mutagenicity induced by Me-lex, a sequence-selective N3-adenine methylating agentPaola Monti, Paola Campomenosi, Yari Ciribilli, et al.
Frontiers in Oncology|November 16, 2020
Heterogeneity of <i>TP53</i> Mutations and P53 Protein Residual Function in Cancer: Does It Matter?Paola Monti, Paola Menichini, Andrea Speciale, et al.
Scientific Reports|September 15, 2018
Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulationBarbara Marengo, Paola Monti, Mariangela Miele, et al.
Human Mutation|March 7, 2013
EEC- and ADULT-associated TP63 mutations exhibit functional heterogeneity toward P63 responsive sequencesPaola Monti, Debora Russo, Renata Bocciardi, et al.
Cells|January 12, 2021
Antitumor Effects of PRIMA-1 and PRIMA-1<sup>Met</sup> (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Paola Menichini, Paola Monti, Andrea Speciale, et al.
Nucleic Acids Research|July 30, 2013
Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence codeYari Ciribilli, Paola Monti, Alessandra Bisio, et al.
Journal of Personalized Medicine|February 10, 2021
Potential Role of miRNAs in the Acquisition of Chemoresistance in NeuroblastomaBarbara Marengo, Alessandra Pulliero, Maria Valeria Corrias, et al.
Frontiers in Immunology|September 8, 2023
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancersChiara M Biatta, Michele Paudice, Marco Greppi, et al.
European Journal of Haematology|March 4, 2021
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocolFortunato Morabito, Giovanni Tripepi, Ernesto Vigna, et al.
Non-Coding RNA|March 19, 2020
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical OutcomeDomenica Ronchetti, Vanessa Favasuli, Paola Monti, et al.
Pageof 7